Pregled bibliografske jedinice broj: 1080337
Dysregulated Ribosome Biogenesis Reveals Therapeutic Liabilities in Cancer
Dysregulated Ribosome Biogenesis Reveals Therapeutic Liabilities in Cancer // Trends in Cancer, 7 (2021), 1; 57-76 doi:10.1016/j.trecan.2020.08.003 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 1080337 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Dysregulated Ribosome Biogenesis Reveals
Therapeutic Liabilities in Cancer
Autori
Bursać, Slađana ; Prodan, Ylenia ; Bartek, Jiri ; Volarević, Siniša
Izvornik
Trends in Cancer (2405-8025) 7
(2021), 1;
57-76
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
dysregulated RiBi in cancer ; IRBC ; p53 ; RiBi inhibitors in cancer therapy
Sažetak
Ribosome biogenesis (RiBi) is one of the most complex and energy demanding processes in human cells, critical for cell growth and proliferation. Strong causal links between inherited and acquired impairment in RiBi with cancer pathogenesis are emerging, pointing to RiBi as an attractive therapeutic target for cancer. Here, we will highlight new knowledge about causes of excessive or impaired RiBi and the impact of these changes on protein synthesis. We will also discuss how new knowledge about secondary consequences of dysregulated RiBi and protein synthesis, including proteotoxic stress, metabolic alterations, adaptive transcriptional and translational programs, and the impaired ribosome biogenesis checkpoint (IRBC) provide a foundation for the development of new anticancer therapies.
Izvorni jezik
Engleski
Znanstvena područja
Biologija, Temeljne medicinske znanosti, Biotehnologija u biomedicini (prirodno područje, biomedicina i zdravstvo, biotehničko područje)
POVEZANOST RADA
Ustanove:
Medicinski fakultet, Rijeka
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE
